
This study aimed to establish a neural‐related gene risk score (NRGRS) for predicting the prognosis of head and neck squamous cell carcinoma. It also explored its predictive value on the benefit of immune checkpoint inhibitor therapy. NRGRS‐high patients had a worse overall survival than NRGRS‐low patients. NRGRS strongly correlates with survival and is a promising biomarker to predict immunotherapy benefits for head and neck cancer patients. In addition, this study provides evidence for the potential correlation between neural‐related transcriptome alteration and immune activity.
Like
Save
Share